Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
CAMBRIDGE, Mass., March 05, 2018 -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences.
Cowen and Company 38th Annual Health Care Conference
Monday, March 12, 2018 at 12:00 p.m. ET in Boston, MA
Barclays Global Healthcare Conference
Wednesday, March 14, 2018 at 2:35 p.m. ET in Miami, FL
A webcast of each presentation will be available live on the “Investors” section of the company’s website located at www.momentapharma.com. A replay of each presentation will be posted on the Momenta website approximately one hour after the event.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Contact:
Sarah Carmody
Momenta Pharmaceuticals
1-617-395-5189
[email protected]
